Home Innovation Innovative Biologics Research Institute

Biologics are a special type of powerful drugs such as recombinant proteins, microorganisms, cells and other biological products obtained by the application of genetic engineering, cell engineering, protein engineering, fermentation engineering and other biotechnologies. Biologics, especially antibody drugs as an effective treatment approach,  has been developed rapidly in recent years. It brings hope to more patients with better efficacy and less side effects for many common diseases including cancer. It can also significantly improve patients' survival rate and quality of life.

R & D Overview

Focusing on innovative biologics R&D, mainly antibody therapeutics, we have constructed three support systems, built up four departments and five core technology platforms to support the whole process of biologics R&D from discovery to IND filing. 

We are committed to develop safe and highly effective biologics to meet major unmet medical needs by focusing on oncology, respiratory diseases, kidney illnesses and infectious diseases.

We have established a complete R&D system and advanced technical platforms from discovery, process development and manufacturing, pre-clinical study to clinic trial to allow development of various biologics such as monoclonal antibodies, bi-specific antibodies, and fusion proteins. 

Mechanisms of Action of Therapeutic Antibodies

Ongoing Projects

Pipeline S/N Product number Product introduction
1 JYB1931 JYB1931 is an innovative therapeutic antibody designed for kidney disease. It has clear mechanism of action and shows high specificity with the potential to become one of the top-tier drug candidates in this area.
Oncology 2 JYB1907 JYB1907 is an innovative therapeutic antibody designed for multiple solid tumors. It shows high affinity and specificity in vitro, as well as high efficacy and extremely low toxicity in vivo. It’s expected to become a first-in-class drug candidate.
3 JYB1908 JYB1908 is an innovative therapeutic antibody designed for multiple solid tumors. It’s against a novel target and showed strong anti-tumor effect. It could potentially become a blockbuster drug of the post anti-PD-1 era.
4 JMB2003 JMB2003 is an innovative bi-specific antibody designed for multiple solid tumors. Developed with Jemincare’s proprietary platform, this bi-specific antibody is designed to target tumor cells and the tumor microenvironment for dual anti-tumor effect.
5 JMB2005 JMB2005 is a bi-specific antibody developed from in house bi-specific antibody platform for the indication of a variety of solid tumors. It showed desired biological function ex vivo, potent efficacy in vivo and favorable developability. It has potential to become a next generation anti-PD-1 therapeutics.
Respiratory Diseases 6 JMB2002 JMB2002 is an innovative broad-spectrum neutralization antibody for the indication of COVID-19. The phase I clinical trial of our anti-SARS-CoV-2 specific neutralizing antibody showed excellent pharmacokinetics and good safety without serious adverse events (SAEs) in all enrolled subjects.
7 JYB1904 JYB1904 is a bio-better antibody drug for the indication of respiratory diseases. It has higher affinity, more-potent efficacy in vivo, longer half-life compared to the Reference Listed Drug (RLD) and provides an injection formulation for more convenient clinical administration.
8 JYB1909 JYB1909 is an innovative antibody for the indication of respiratory diseases. The advantages of this antibody are high affinity and better biological activity, it will fill the unmet clinical needs of this indication.

R & D Team

56% scientists with MS degree
11% scientists with PhD degree

The Innovative Biologics Research Institute has a team of 60 scientists, of whom 11% hold PhD degree and 56% hold MS degree. The top management team consists of scientists with more than 20 years of oversea Biopharma and Biotech industrial experiences. 

PtY (Phage-to-Yeast) Antibody Discovery Platform

Based on our high quality human naive antibody library, the technologies of phage antibody display and yeast antibody display are integrated into a platform named as PtY (Phage-to-Yeast) antibody discovery platform. It has the unique advantages of high throughput from phage display and real-time visualization and multi-dimensional screening from yeast display. In practice, it can rapidly and precisely screen out antibody candidates that recognize unique epitopes for drug targets and greatly shorten the timeline of antibody discovery.